Development of a smartphone screening test for preclinical Alzheimer's disease and validation across the dementia continuum

Author:

Alty Jane1,Goldberg Lynette R.1,Roccati Eddy1,Lawler Kate2,Bai Quan1,Huang Guan1,Bindoff Aidan D.1,Li Renjie1,Wang Xinyi1,St George Rebecca1,Rudd Kaylee1,Bartlett Larissa1,Collins Jessica1,Aiyede Mimieveshiofuo1,Fernando Nadeeshani3,Bhagwat Anju3,Giffard Julia1,Salmon Katharine1,McDonald Scott1,King Anna1,Vickers James1

Affiliation:

1. University of Tasmania

2. La Trobe University

3. Royal Hobart Hospital

Abstract

Abstract Background Dementia prevalence is predicted to triple to 152 million globally by 2050. Alzheimer's disease (AD) constitutes 70% of cases. There is an urgent need to identify individuals with preclinical AD (a 10–20-year period of progressive brain pathology without noticeable cognitive symptoms) for targeted risk reduction. Current tests of AD pathology are either too invasive, specialised or expensive for population-level assessments. Cognitive tests are normal in preclinical AD. Emerging evidence demonstrates that movement analysis is sensitive to AD across the disease continuum, including preclinical AD. Our new smartphone test, TapTalkTest combines analysis of hand and speech-like movements to detect AD risk. This study aims to (1) determine which combinations of hand-speech movement data most accurately predict preclinical AD, (2) determine usability, reliability, and validity of TapTalkTest in cognitively asymptomatic older adults and, (3) prospectively validate TapTalkTest in older adults who have cognitive symptoms against cognitive tests and clinical diagnoses of Mild Cognitive Impairment and AD dementia. Methods Aim 1 will be addressed in a cross-sectional study of 500 cognitively asymptomatic older adults who will complete computerised tests comprising measures of hand motor control (finger tapping) and oro-motor control (syllabic diadochokinesis). Motor measures will be compared to a blood-based AD biomarker, phosphorylated tau 181 to develop an algorithm that classifies preclinical AD risk. Aim 2 comprises three sub-studies in cognitively asymptomatic adults: (i) a cross-sectional study of 30-40 adults to determine the validity of data collection from different types of smartphones, (ii) a prospective cohort study of 50-100 adults ≥50 years old to determine usability and test-retest reliability, and (iii) a prospective cohort study of ~1,000 adults ≥50 years old to validate against cognitive measures. Aim 3 will be addressed in a cross-sectional study of ~200 participants with cognitive symptoms to validate TapTalkTest against Montreal Cognitive Assessment and interdisciplinary consensus diagnosis. Discussion This study will establish the precision of TapTalkTest to identify preclinical AD and estimate risk of cognitive decline. If accurate, this innovative smartphone app will enable low-cost, accessible screening of individuals for AD risk. This will have wide applications in public health initiatives and clinical trials. Trial registration: ClinicalTrials.gov identifier: NCT06114914, 29 October 2023. Retrospectively registered.

Publisher

Research Square Platform LLC

Reference66 articles.

1. Dementia prevention, intervention, and care;Livingston G;Lancet,2017

2. Dementia in Australia., Summary 2023 [Available from: https://www.aihw.gov.au/reports/dementia/dementia-in-aus/contents/summary.

3. Global action plan on the public health. response to dementia 2017–2025. https://www.who.int/publications/i/item/global-action-plan-on-the-public-health-response-to-dementia-2017---2025: World Health Organisation; 2017.

4. Risk reduction of cognitive decline and dementia. WHO guidelines. World Health Organisation; 2019. https://www.who.int/publications/i/item/9789241550543.

5. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission;Livingston G;Lancet,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3